Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab
Authors
Keywords
-
Journal
CANCER
Volume 118, Issue 17, Pages 4173-4183
Publisher
Wiley
Online
2011-12-28
DOI
10.1002/cncr.27396
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma
- (2010) Matija Snuderl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Double-hit B-cell lymphomas
- (2010) S. M. Aukema et al. BLOOD
- Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
- (2010) Sharon Barrans et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era
- (2010) Marita Ziepert et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
- (2009) N. A. Johnson et al. BLOOD
- MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
- (2009) K. J. Savage et al. BLOOD
- Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP
- (2009) J. Shustik et al. HAEMATOLOGICA
- BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome
- (2009) Maria Grazia Tibiletti et al. HUMAN PATHOLOGY
- Immuno–Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study
- (2009) Christiane Copie-Bergman et al. JOURNAL OF CLINICAL ONCOLOGY
- BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma
- (2009) E C Obermann et al. JOURNAL OF CLINICAL PATHOLOGY
- Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment
- (2009) E C Obermann et al. JOURNAL OF CLINICAL PATHOLOGY
- Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations
- (2009) N Niitsu et al. LEUKEMIA
- A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
- (2008) G. M. Mead et al. BLOOD
- Clinical significance of 8q24/c-MYCtranslocation in diffuse large B-cell lymphoma
- (2008) Nozomi Niitsu et al. CANCER SCIENCE
- MYCtranslocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type
- (2008) S O Yoon et al. HISTOPATHOLOGY
- Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma
- (2008) Kai Fu et al. JOURNAL OF CLINICAL ONCOLOGY
- Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study
- (2008) H A Poirel et al. LEUKEMIA
- Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
- (2008) W Klapper et al. LEUKEMIA
- LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab
- (2007) Yasodha Natkunam et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started